What Felogel Treats: Main Uses and Benefits

Felogel is a non-steroidal anti-inflammatory drug (NSAID) gel, which is commonly used to help with the localized easing of inflammation and pain.

Targeted Symptomatic Relief for Musculoskeletal Discomfort

Felogel is commonly used to provide symptomatic support for the localized pain and stiffness associated with osteoarthritis and for acute management of soft tissue injuries, including minor sprains, strains, and contusions (bruises). This application is generally considered relevant in conditions where symptoms may intensify temporarily, and the goal is to ease the overall symptom burden.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, such as following a sports-related strain, or during a chronic flare-up of localized joint pain. It is relevant for managing symptoms that create noticeable physiological strain and may assist the patient during difficult episodes.

“Topical NSAIDs are relevant for easing symptoms that interfere with daily functioning, allowing patients to cope more steadily with symptom fluctuations.”

This application is considered relevant for easing symptoms that interfere with daily functioning, and may help patients cope more steadily with symptom fluctuations. It can assist with maintaining functional stability and contributes to easing the overall symptom load.

Quick Fact: Relief for Localized Musculoskeletal Symptoms
Primary Focus	Localized pain, stiffness, and inflammation
Key Scenarios	Osteoarthritis of the knee/hand; acute sprains/strains
Patient Benefit	Contributes to easing the overall symptom load

Official Eligibility Rules for Felogel

Regulatory documents define specific populations who are permitted, restricted, or prohibited from using Felogel (Topical Diclofenac NSAID).

Classification	Eligibility Statement
Contraindicated	Individuals with a known hypersensitivity to diclofenac, aspirin, or any other NSAIDs. This includes a history of asthma, urticaria, or allergic-type reactions after taking NSAIDs [Source 1.1, 1.5].
Contraindicated	Patients in the third trimester of pregnancy (starting at 30 weeks gestation) due to the risk of fetal harm [Source 1.5, 2.3].
Contraindicated	Patients in the perioperative period of Coronary Artery Bypass Graft (CABG) surgery [Source 1.1, 1.5].
Contraindicated/Not Established	Children and adolescents below 14 years of age due to insufficient data on safety and efficacy [Source 3.2, 3.4].
Restricted	Avoid use in patients with advanced renal disease or severe heart failure unless the benefits are expected to clearly outweigh the risk of worsening function [Source 1.5, 2.3].
Restricted	Use is limited to intact, non-diseased skin and is prohibited on open wounds, damaged skin, or lesions [Source 1.1].
Permitted	Adults are generally eligible for use. Older adults may use the product, but monitoring is advised due to potential age-related risks (e.g., renal impairment) [Source 1.3, 3.4].

Interactions with other medicines and products

The official regulatory profile for Felogel, which contains the active ingredient Diclofenac, documents specific interactions primarily driven by the drug's classification as a Non-Steroidal Anti-Inflammatory Drug (NSAID).

Felogel is strictly contraindicated for use in patients with a history of allergic-type reactions to Aspirin or other NSAIDs (Aspirin-sensitive asthma) and in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery.

Category	Officially Documented Interaction Restrictions
Co-administration Avoidance	Oral NSAIDs and Analgesic Doses of Aspirin must not be used concurrently due to the synergistic increase in risk for serious gastrointestinal adverse events, including bleeding.
Pharmacodynamic Risk	Concurrent use with Anticoagulants (such as Warfarin) or other medications that interfere with hemostasis increases the documented risk of serious gastrointestinal bleeding.
Efficacy Modification	Co-administration may diminish the antihypertensive effect of ACE Inhibitors, ARBs, and Beta-Blockers. Diuretics, such as Furosemide or Thiazides, may also experience a reduced natriuretic effect.
Drug Concentration	Concomitant use with Digoxin is documented to potentially increase the serum concentration and prolong the half-life of Digoxin.
Timing/Substance	Alcohol consumption may increase the risk of stomach bleeding. Additionally, regulatory documents require patients to avoid concomitant application of other topical products to the treated skin site.
Population Notes	In elderly patients or those with existing renal or heart impairment, the documented risk of renal deterioration when using ACE Inhibitors or ARBs is heightened.

How Felogel Works: The Mechanism of Action

Felogel's active ingredient exerts its effect through targeted enzymatic inhibition localized to the periphery. The molecule primarily engages the Cyclooxygenase (COX) enzyme system, which is central to the biosynthesis of inflammatory mediators. By acting as a non-selective inhibitor of both COX-1 and COX-2 enzymes, the drug prevents the conversion of arachidonic acid into prostaglandins—chemical mediators that facilitate nociceptor sensitization and localized vascular changes.

This molecular suppression produces two key physiological consequences at the site of application: it reduces the chemical sensitization of peripheral nociceptors (pain receptors), resulting in a functional elevation of the local nociceptive threshold. Simultaneously, it reverses the prostaglandin-driven vasodilation and increased vascular permeability, which is the physiological process that leads to the accumulation of interstitial fluid, thereby mitigating localized edema. This mechanism's efficacy is strictly dependent on local tissue accumulation and does not alter the underlying structural or pathological progression of chronic conditions.

The administration of Felogel (Diclofenac Topical Gel, 1%) follows specific procedural instructions, ensuring use is strictly confined to the topical (cutaneous) route. The standard regimen involves a fixed application frequency of four times daily at regular intervals to the affected joint area.

Precise Dosing and Measurement

To maintain consistency with the dose, the medicine must be measured using the dosing card supplied with the carton. The required amount of gel varies depending on the joint being treated. The maximum total daily dose, across all treated body areas, is 32 g.

Treated Joint Area	Dose per Application	Maximum Daily Dose (per joint)
Upper Extremities (Hand, Wrist)	2 g	8 g
Lower Extremities (Knee, Ankle)	4 g	16 g

Application Timing and Restrictions

The protocol requires the gel to be applied only to intact skin and restricts application to a maximum of two body areas concurrently. Following application, the treated area must not be covered with an airtight (occlusive) dressing. Specific timing constraints apply: hands must be washed immediately after use, unless the hands are the site of treatment, in which case washing must be delayed by at least one hour. Patients should also avoid showering or bathing for at least one hour. The administration protocol applies to those aged 14 years and older.

Research Evidence / Overview of Studies for Felogel

---

Evidence for Use in Localized Osteoarthritis (OA)

The research foundation for the application of topical diclofenac gel in conditions like osteoarthritis (OA) of superficial joints (such as the knees and hands) includes Randomized Controlled Trials (RCTs) and systematic reviews. These studies were designed to monitor outcomes related to physical discomfort and to measure changes in daily functioning or activity level in adults diagnosed with mild to moderate OA. Research examined how symptoms evolved in the observed populations when the gel was applied compared to when an inactive vehicle gel was used.

In these trials, researchers focused on patient-reported outcomes describing perceived discomfort using standardized pain scales. Findings describe patterns observed in the studies related to temporary changes in pain intensity when compared to the placebo vehicle. Research has focused on superficial joints like the hand and knee; consequently, there is limited evidence for application on deeper joints, such as the hip.

---

Evidence for Use in Acute Soft Tissue Injuries

Topical diclofenac gel was evaluated in research exploring short-term symptom changes for acute, localized soft tissue injuries, including minor sprains, strains, and contusions. The key evidence for this use is drawn from short-term RCTs and subsequent meta-analyses. These trials focused on outcomes describing episodic or acute changes over defined time intervals.

Studies explored the changes measured during the very short follow-up period, which was typically limited to one or two weeks. Research highlights changes measured for outcomes related to physical discomfort and functional impairment following injury. Since the research was designed to examine temporary physiological imbalance, the follow-up durations were limited, and the results apply only to the adult populations studied for these minor, acute injuries.

---

Pharmacokinetic Studies and Systemic Exposure

Beyond clinical outcomes, research has examined how the gel's active ingredient is absorbed into the body. These specialized pharmacokinetic (PK) studies explored drug absorption patterns following topical application. Data show patterns related to absorption, indicating that the amount of the drug entering the bloodstream (systemic exposure) is substantially lower compared to taking an oral form of the same medicine. It is important to understand that these PK studies examine temporary physiological imbalance and absorption—they do not directly evaluate clinical outcomes.

Key Studies & References

1. Management of osteoarthritis (NICE Guideline NG226, 2022) - Topical NSAID Recommendation
2. Diclofenac sodium topical gel - Prescribing Information / DailyMed (FDA/NIH Regulatory Data)

Common questions about Felogel (FAQ)

---

Q: What should I do if I accidentally swallow Felogel?

A: Felogel is for topical, external use only. If a large amount of the gel is accidentally swallowed, official instructions indicate that contacting a poison control center or seeking emergency medical attention is recommended, as this product is not intended to be taken by mouth.

---

Q: What are the ingredients in Felogel besides Diclofenac?

A: The active ingredient in Felogel is Diclofenac. The official product label lists several inactive ingredients (excipients) used to form the gel base. These ingredients typically include substances such as isopropyl alcohol, propylene glycol, purified water, and various stabilizers needed to create the topical formulation.

---

Q: Does Felogel interact with vitamins or herbal supplements?

A: Official regulatory documents primarily detail interactions with prescription and over-the-counter medicines. However, official information advises patients to tell their healthcare professional about all products they are using, including herbal remedies, vitamins, or supplements. Combination data for these products are often not readily available in the same way as for prescription drugs.

---

Q: How long after the tube is opened does Felogel expire?

A: The expiration date printed on the tube applies to the unopened package. For medicines used repeatedly, some guidance suggests a Beyond-Use Date once the container is first opened. The recommended discard period can often be 6 months for certain topical, water-containing formulations. It is important to review the product labeling for specific instructions regarding the discard date for the tube you are using.

How to Store and Dispose of Felogel?

Felogel (diclofenac topical gel) must be stored according to specific regulatory requirements to maintain its integrity and stability.

Storage Conditions

The gel should be stored at controlled room temperature, generally between 20 C and 25 C, though some regional labels permit storage up to 30 C. It is mandatory to keep the product from freezing and protect it from direct light. The gel must be kept in its original, closed container.

Quick Fact: Storage Stability
Temperature Requirement	Controlled Room Temperature
Prohibited Condition	Do Not Freeze
Protection Rule	Store in Original Container to Protect from Light

Child Safety and Disposal

It is required to keep Felogel out of the reach of children. The shelf-life after first opening the tube may be specified, such as 6 months for certain formulations; unused or outdated medicine should not be kept. Disposal of any unused or expired product must be carried out in accordance with local regulatory requirements, with specific instructions to prevent the product from reaching the aquatic environment.